摘要
目的分析HIV-1型艾滋病合并结核病患者的耐药基因,探讨与艾滋病患者之间的耐药差异。方法随机对2014年12月至2016年5月在河南省传染病医院住院的艾滋病合并结核病(AIDS/TB)患者和单独艾滋病(AIDS)患者各55例进行HIV病毒载量检测,对HIV载量>1000copies/ml者再用Viro Seq试剂进行HIV-1耐药基因检测。结果纳入HIV-1检测分析的有AIDS/TB组18例,总耐药率50.00%;AIDS组50例,总耐药率76.00%(χ~2=3.48,P>0.05)。两组患者对NRTI类、NNRTI、PI类各种抗病毒药物的耐药情况无统计学差异。AIDS/TB组M184位点的突变频率为27.78%,低于AIDS组的56.00%(χ~2=4.22,P<0.05);AIDS/TB组K130位点的突变频率为16.67%,AIDS组为46.00%,二者差异有统计学意义(χ~2=4.82,P<0.05);其余突变位点均无统计学差异。结论与AIDS患者一样,AIDS/TB患者对三类抗病毒药物也有不同程度的耐药,其中3TC、FTC、NVF为耐药率最高的药物;AIDS/TB患者耐药突变位点与单独AIDS患者略有差异。
Objective To study the genetic variation and drug resistance of HIV-1 in patients with AIDS combined with tuberculosis（ AIDS/TB）,investigate the difference from the patients with AIDS alone. Methods HIV virus load was detected in 55 patients with AIDS/TB and 55 patients with AIDS alone from December 2014 to May 2016 in our hospital. When the HIV load was 〉1000 copies/ml,the HIV-1 resistance gene was detected by Viro Seq reagent. Results Totally 18 cases of AIDS/TB group and 50 cases of AIDS group had HIV-1 resistance gene detection. The total drug resistance rate were respectively 50. 00% and 76. 00%（ χ~2= 3. 48,P〉0. 05）. There was no significant difference between the two groups in the resistance to NRTI,NNRTI,and PI. The mutation frequency of M184 locus in group AIDS/TB was 27. 78%,which was lower than that of group AIDS（ χ~2= 4. 22,P〈0. 05）. The mutation frequency of K130 locus in group AIDS/TB and group AIDS were respectively 16. 67% and 46. 00%,the difference between the two groups was statistically significant（ χ~2= 4. 82,P〈0. 05）. Conclusion As well as AIDS patients,AIDS/TB patients have different degree of resistance to all kinds of HAART drugs,including 3TC,FTC,NVF as the most drug resistance rate. Some mutation sites in AIDS/TB patients were significantly different from those of patients with AIDS alone.
出处
《医药论坛杂志》
2017年第7期1-4,共4页
Journal of Medical Forum
基金
河南省医学科技攻关计划项目(201403244)
